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ABSTRACT
We report anticarcinogenic effects of suicide gene therapy that relies on the use
of resveratrol-responsive CArG elements from the Egr-1 promoter to induce GADD45α.
In A549 lung cancer cells, endogenous GADD45α was not induced upon resveratrol
treatment. Therefore, induction of exogenous GADD45α resulted in growth inhibition.
Resveratrol transiently induced Egr-1 through ERK/JNK-ElK-1. Hence, we cloned
natural or synthetic Egr-1 promoter upstream of GADD45α cDNA to create a suicide
gene therapy vector. Since natural promoter may have antagonized effects, we tested
synthetic promoter that contains either five, six or nine repeats of CArG elements
essential in the Egr-1 promoter to drive the expression of GADD45α upon resveratrol
treatment. Further analysis confirmed that both synthetic promoter and natural Egr1 promoter were able to “turn on” the expression of GADD45α when combined with
resveratrol, and subsequently led to suppression of cell proliferation and apoptosis.

INTRODUCTION

arrest G2/M transition through disrupting Cdk1/Cyclin
B1 interaction after DNA damage [5], and interestingly,
GADD45α-mediated G2/M arrest is dependent on normal
p53 function [1]. Other possible roles of GADD45α
include activating p38/JNK pathway which is associated
with apoptosis [6], regulating Aurora-A and Nek2
which have functions in the maintenance of genomic
stability [3], disrupting elongation factor 1α (EF-1α)mediated microtubule bundling to induce apoptosis
[12], and suppressing mTOR/STAT3 pathway to restrain
angiogenesis [7]. Previous studies have demonstrated
that inactivation of GADD45α may associate with the
development of malignancy as GADD45α-null mice
and p53-deficient mice have similar phenotypes such
as increased radiation carcinogenesis, a low frequency
of exencephaly and genomic instabilities which are
exemplified by aneuploidy, chromosomal aberrations,
gene amplification, centrosome amplification, abnormal
mitosis and cytokinesis [35]. Besides, GADD45α-null

Lung cancer is the leading cause of cancerrelated death in both men and women around the world.
Approximately 85% of all lung cancers are non-small cell
lung carcinoma (NSCLC), with lung adenocarcinoma
being the most common histologic type in the United
States. Most patients with advanced stage disease are
not candidates for surgical resection but are subjected to
platinum based chemotherapy and radiation therapy alone
or in combination. Unfortunately, despite these therapies,
prognosis is still poor with an overall 5-year survival rate
of only 15% [2].
Growth arrest and DNA damage inducible 45α
(GADD45α) is a stress-inducible gene transcriptionally
activated by growth-arrest-associated proteins including
p53, FOXO3a, ATF4 and C/EBP, and repressed by
growth stimulating factors such as c-Myc and AKT [3].
The main function of GADD45α in the cell cycle is to
www.impactjournals.com/Genes&Cancer
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mice are susceptible to DNA damage-induced tumors [36].
Downregulation and aberrant expression of GADD45α
have been established in many types of cancer. Higashi et
al. showed that GADD45α mRNA level was 90% lower
in NSCLC tumors than that in histological normal lung
tissues [8]. Al-Romaih et al. reported GADD45α was
epigenetically inactivated in various types of tumor cell
lines such as osteosarcoma cells [9]. Importantly, the fact
that reactivation of GADD45α results in the induction
of cancer cell apoptosis validates the feasibility of
GADD45α-targeted cancer therapy [6, 10-12]. A recent
report showed an increased suppression in pancreatic
cancer cell growth through inducing apoptosis and cell
cycle arrest after cells were transfected with adenoviral
construct of GADD45α [37].
Early growth response 1 (Egr-1) is a transcription
factor rapidly and transiently induced by a broad variety
of stimuli such as growth factors [13], differentiation
signals [14], ionizing radiation (IR) [15] and shear
stress [16]. It directly binds to GADD45α promoter and
activates the transcription of GADD45α upon UVB
exposure [32] or arsenic insult [17]. The activation
of Egr-1 is p53-independent and the radiation and
chemotherapy-inducible regions of Egr-1 promoter have
been identified as 10-nucleotide motifs of the consensus
sequence CC(A/T)6GG which are also known as CArG
elements [18-19]. The CArG elements are often referred
to as serum response elements (SREs) and involved in
the regulation of multiple immediate-early genes after
mitogenic stimulation [26]. The precise mechanism of
radiation- and chemotherapy-responsive property of CArG
elements has yet to be elucidated. Reactive oxygen species
(ROS) formation through radiation and chemotherapy
is one explanation, and complexes of phosphorylated
transcription factors and accessory proteins are known
to promote gene transcription by binding to CArG
motifs [20]. In addition, only the CArG elements in the
5’ distal enhancer region of Egr-1 gene appear to be
responsive to radiation and chemotherapeutic agents [21].
A 425-nucleotide region of murine Egr-1 promoter was
sufficient to drive the expression of tumor necrosis factor
α (TNFα) beyond activation when being inserted upstream
of TNFα cDNA [22]. Furthermore, Scott et al. found that
increasing the number of CArG elements and altering the
core A/T sequence in these motifs enhanced promoter
radiation-responsiveness [20].
Resveratrol is a phytochemical found in several
dietary sources, and it is a leading candidate in the fight
against age-related disorders. Resveratrol affects the
activity of transcriptional factors involved in proliferation
and stress responses such as NF-kB, AP1 and Egr1 [24], and targets signaling pathways regulating cell
proliferation, growth and apoptosis, inflammation,
and tumor invasion, angiogenesis and metastasis [23].
Resveratrol is well tolerated and relatively safe [38],
so has been considered as an extended candidate in
www.impactjournals.com/Genes&Cancer

TNFerade study to benefit patients who cannot tolerate
even low doses of radiation or chemotherapy and for
long-term gene therapy application [25]. TNFerade is a
replication-deficient adenovector carrying CArG elements
to regulate the expression of TNFα, a pro-apoptotic
cytokine. TNFerade has been effective in combination
with radiotherapy or chemotherapy in preclinical studies,
leading to direct tumor killing, anti-angiogenesis and
synergistic interaction with radiation or chemotherapeutic
agents, and has passed phase I/II clinical trials for
pancreatic cancer [41].
The overall goal of our study is to establish a novel
treatment paradigm for NSCLC by creating a suicide gene
therapy vector that expresses GADD45α protein under the
control of resveratrol-activated CArG elements. Here, we
determined the MAPKs involved in resveratrol-induced
Egr-1 expression and assessed the therapeutic efficacy of
our suicide gene therapy strategy.

RESULTS
Induction of Egr-1 expression by resveratrol in
lung cancer cells
Resveratrol is able to activate Egr-1 expression in
several cancers including pancreatic [25] and colorectal
cancer [27]. To determine whether resveratrol is an
effective inducer of Egr-1 expression in lung cancer,
A549 cells were incubated with 100 µM of resveratrol,
and mRNA level and protein expression were measured
at different time points by real-time RT-PCR and western
blotting respectively. The induction of Egr-1 mRNA and
protein reached maximum 2 h and 4 h respectively after
resveratrol treatment (Figure 1A and 1B). In addition, the
expression of Egr-1 protein was measured after cells were
treated with 0, 25, 50 and 100 µM of resveratrol for 6 h,
and a dose-dependent induction was detected (Figure 1C).
Fluorescence in situ hybridization (FISH) assay reinforced
that Egr-1 mRNA level was significantly induced 2 h after
resveratrol exposure (Figure 1D). These results suggest
that resveratrol is able to induce Egr-1 expression rapidly
and transiently.

Characterization of Elk-1 expression following
resveratrol treatment
Elk-1 is a major downstream of the MAPK pathway
and its activation leads to increased DNA binding, ternary
complex formation and SRE-mediated transcription [28].
As shown previously, resveratrol induced apoptosis in
both thyroid cancer cells and JB6 mouse epidermal cells
in a MAPK-dependent manner [29, 30]. To determine
whether Elk-1 is a participator in resveratrol-activated
signaling cascade, Elk-1 protein levels were determined
221

Genes & Cancer

after cells were treated with indicated concentrations of
resveratrol for indicated hours. The results showed that
Elk-1 protein expression was increased by resveratrol
in a time- and dose-dependent manner (Figure 2A and
2B). The resveratrol-induced Elk-1 expression was also
confirmed by immunofluorescence staining in which the
expression of Elk-1 protein was significantly augmented
by overnight treatment with resveratrol (100 µM) (Figure
2C). Taken together, Elk-1 is confirmed as a target of
resveratrol in lung cancer.

mediated Egr-1 induction (Figure 3A, lane 6 and 8),
whereas SB 203580 and LY 294002 had no significant
effects on resveratrol-induced Egr-1 protein expression
(Figure 3A, lane 4 and 10). Given that Elk-1 is a welldescribed downstream target of MAPK pathways as
well as a potential regulator of Egr-1 promoter [31], we
investigated whether resveratrol-induced Egr-1 expression
relies on Elk-1 activity. The results demonstrated that the
silencing of Elk-1 by siRNA transfection abolished the
induction of Egr-1 protein by resveratrol (Figure 3B). All
the data demonstrate that the normal function of JNK,
ERK and Elk-1 is necessary for resveratrol-activated Egr1 expression, and indicate that JNK/ERK-Elk-1-Egr-1 is
a signaling pathway triggered by resveratrol (Figure 3C).

MAPK and Elk-1 for resveratrol-induced Egr-1
biosynthesis
Activation of individual MAPK by a certain
stimulus depends on the cell line, time and dose applied.
Therefore, it is important to identify the involvement of
each MAPK in resveratrol-mediated Egr-1 induction in
A549 cells. We also tested the role of PI3K/AKT pathway
as it is an important pathway to control multiple cell
functions including cell proliferation, growth and survival.
Cells were pretreated with p38 inhibitor (SB 203580, 10
µM), JNK inhibitor (SP 600125, 20 µM), ERK inhibitor
(U-0126, 10 µM) and PI3K/AKT inhibitor (LY 294002,
10 µM) respectively for 1 h and then exposed to either
0.1% DMSO or 100 µM of resveratrol for additional 6
h. The analysis of Egr-1 protein levels indicated that
SP 600125 and U-0126 were able to block resveratrol-

Marginal effects of resveratrol on GADD45α
expression in lung cancer
As we previously reported, Egr-1 directly binds
to GADD45α promoter and activates GADD45α
transcription in the presence of arsenic in normal lung
cells [17]. To determine whether resveratrol is able to
induce GADD45α in lung cancer, A549 cells were treated
with 100 µM of resveratrol up to 24 h and both mRNA
level and protein expression were measured. GADD45α
mRNA was slightly increased in a time-dependent
manner (Figure 4A) but GADD45α protein was not
detected by western blotting (Figure 4B). Moreover, in

Figure 1: Resveratrol induces Egr-1 expression. A. A549 cells were treated with 100 µM of resveratrol for indicated hours and

Egr-1 mRNA levels were measured by real-time RT-PCR. The Egr-1 mRNA expression was adjusted to GAPDH (housekeeping gene)
and normalized to untreated control. B. and C. Egr-1 and β-actin (loading control) protein expression was determined by western blotting
after indicated resveratrol treatment. D. Fluorescent In Situ Hybridization assay was used to detect Egr-1 mRNA level in non-treated and
resveratrol-treated cells. Images were taken on Axio Imager M2 at 400X magnification.
www.impactjournals.com/Genes&Cancer
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Therapeutic effects of suicide gene therapy

immunofluorescence staining, no significant change was
observed regarding GADD45α protein expression between
cells treated with 100 µM of resveratrol overnight and
non-treated cells (Figure 4C). In conclusion, our data
suggest that resveratrol has limited effects on the induction
of GADD45α expression.

To confirm the overexpression of GADD45α protein
through the combination of our gene therapy vector and
resveratrol treatment delays lung cancer progression and
increases cancer cell apoptosis, we transfected A549 cells
with pT.Luc (control vector), pE9NS.G45α or pE460.G45α
for 24 h and then treated with either 0.1% DMSO or 100
µM of resveratrol for additional 24 h before proceeding
to western blotting, MTT assay and Annexin-V/propidium
iodide (PI) flow cytometric analysis. Immunoblotting
data depicted that both pE9NS.G45α and pE460.G45α
were able to drive the expression of GADD45α in A549
cells when activated by resveratrol (Figure 5B). The data
from MTT assay and flow cytometric analysis suggested
resveratrol alone had marginal suppression in cell growth
and negligible induction in apoptosis, but resveratrol
plus gene therapy vector (pE9NS.G45α or pE460.G45α)
exhibited less than 50% cell viability and approximately
20% higher apoptosis as opposed to control (Figure 5C
and 5D). Transfection with gene therapy vector but
without resveratrol treatment did not significantly affect
cell growth or apoptosis in these cells (Figure 5C and 5D).

Optimization of resveratrol-responsive synthetic
Egr-1 promoters
In order to confirm the potential of combining
CArG-mediated gene therapy with resveratrol, we
tested the resveratrol-responsiveness of synthetic
promoters E5 (five repeats of prototype CArG sequence
(CCTTATTTGG), E6 (six repeats of prototype CArG
sequence) and E9NS (nine repeats of new CArG sequence
(CCATATAAGG), and the natural Egr-1 promoter E460
(460 nucleotides upstream of transcription start site). The
relative luminescence was monitored by dual-luciferase
assay reporter system. All synthetic promoters (E5, E6
and E9NS) were activated 1.75- to 2.25-fold by resveratrol
(Figure 5A). Therefore, due to lack of statistical difference
in resveratrol-responsiveness amongst these synthetic
promoters, further studies only included E9NS promoter
[20].

DISCUSSION
Our study demonstrated that resveratrol activated
Egr-1 biosynthesis via ERK/JNK-Elk-1 signaling

Figure 2: Elk-1 is activated by resveratrol. A. and B. Western blotting was used to detect Egr-1 protein expression in cells treated with

different concentrations of resveratrol for indicated hours. C. Fluorescent In Situ Hybridization staining of Egr-1 and immunofluorescence
staining of Elk-1 in resveratrol-treated cells and control cells. Images were taken on Axio Imager M2 at 400X magnification.
www.impactjournals.com/Genes&Cancer
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pathway in A549 cells. Similarly, Egr-1 has been reported
to be induced by resveratrol through ERK but not p38
pathway in both normal and neoplastic human cells,
and this induction is irrelevant to cellular p53 status
[33]. In erythroleukemic cells, Egr-1 upregulation by
resveratrol requires ERK1/2 activation and contributes
to the chemopreventive and antiproliferative properties
of resveratrol through downstream target p21Cip1 [39]. In
general, instead of causing direct DNA damage, resveratrol
exhibits its effects by interfering with DNA replication
and cell division. Sirtuin 1 (SIRT1) is the major protein
activated by resveratrol, but Bickenbach et al. found that
SIRT1 inhibitor did not block resveratrol-induced Egr-1
expression [25], suggesting that resveratrol upregulates
Egr-1 expression probably through other mechanisms.
The selection of GADD45α as the suicide gene
is based on the assumptions that (i) dysregulation of
GADD45α could be expected in lung cancer; (ii) a correct
sequence of GADD45α can provide therapeutic measures;
(iii) targeting the downstream pathway of signaling
network is the most preferred over an upstream pathway
that may have many biological processes compromised. In
promyelocytic leukemia (HL-60) cells, resveratrol induces
apoptosis through GADD45α upregulation [40]. On the
contrary, in our study the mRNA level of GADD45α
was increased by about 3 folds 24 h after resveratrol

treatment, but no change in protein expression was
detected either by immunofluorescence staining or western
blotting. Furthermore, opposed to the effects in leukemia,
resveratrol only showed weak cytotoxic effects and growth
inhibition in lung cancer cells, indicating that resveratrol
alone may not be effective in lung cancer treatment, but
may facilitate other treatment strategies.
Although GADD45α fails to arrest cell cycle
progression at G2/M checkpoint in p53-deficient cancer
cells, it is still able to suppress cell proliferation via
inducing apoptosis [43], indicating that GADD45αmediated G2/M arrest depends on normal p53 function
whereas GADD45α-induced apoptosis is irrelevant to p53.
MTK1/MEKK4-p38/JNK pathway has been established
as the mechanism through which GADD45α regulates
apoptosis in response to environmental stresses [6], but
the involvement of JNK activation remains controversial
since GADD45α was not necessary in stress-induced JNK
activation [34] and JNK is only marginally activated even
after significant induction of GADD45α in HeLa cells [12].
Recently, Tong et al. posted a novel pathway elucidating
the underlying mechanism of apoptosis mediated by
stress-induced-GADD45α: GADD45α interacts with EF1α, causing cytoskeleton destabilization which induces the
release of Bim and its translocation to mitochondria, and
the successive steps include the release of cytochrome c,

Figure 3: MAPK pathway is involved in resveratrol-induced Egr-1 expression. A. Cells were treated with or without 100 µM

of resveratrol for 6 h after pretreatment with indicated inhibitors for 1 h, and Egr-1 protein level were examined by western blotting. B.
Cells were exposed to 100 µM of resveratrol for 6 h after transfected with either Elk-1 siRNA or Luciferase siRNA. C. The summary of
ERK/JNK-Elk-1-Egr-1 pathway: resveratrol sequentially activates MAPK cascade, Elk-1 and Egr-1.
www.impactjournals.com/Genes&Cancer
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the activation of caspase-9 and caspase-3, and ultimately
apoptosis [12]. In our report, ectopic expression of
GADD45α successfully suppressed cell proliferation and
induced apoptosis in lung cancer. Additional investigations
are required to determine whether the mechanism is
G2/M arrest, destabilized cytoskeleton or enhancement of
other apoptosis/growth arrest-related signaling pathways
activated by resveratrol.
A safety switch, which is inactive but inducible
when combined with low doses of standard regiments
(platinum based therapy and/or radiation therapy) or
natural compounds, could minimize toxicity in normal
tissue and facilitate the controllable applications of gene
therapy. The Egr-1 promoter has been widely studied for
the regulation of therapeutic genes in the experimental
models of radiation- and chemotherapy-mediated gene
therapy, such as Ad.Egr-TNF11D [41] and the EGR1CYP4B1/4-IM system [42]. However, besides the CArG
elements, Egr-1 promoter contains other regulatory sites
including two Sp1 binding sites, a cyclic adenosine
monophosphate (cAMP) response element (CRE), a NFκB binding site and an Egr binding sequence (EBS) [26].
The promoter E460 used in our study only contains 460
nucleotides upstream of Egr-1 transcription start site, but
still includes binding sites for Sp1 and cAMP. Synthetic
alternatives consisting of repeated CArG elements
have been developed in order to eliminate potentially

antagonistic binding sites. Scott et al. have optimized the
synthetic promoter radiation-responsiveness based on
the numbers, core sequences, spacing and context [20].
Among a series of synthetic promoters, the one carrying
nine repeats of new sequence CArG elements but no
extra nucleotide “spacer” sequence nor Sp1 binding site
has obtained the greatest sensitivity to radiation [20].
The later study has demonstrated that the new sequence
CArG element is more sensitive to neutron/X-ray radiation
and chemotherapeutic agents than the prototype CArG
sequence, and the activated synthetic promoter is sufficient
to express downstream HSVtk [4]. In the present study,
we have constructed a natural promoter E460 and three
synthetic promoters E5, E6 and E9NS, and compared their
responses to resveratrol. All promoters were responsive
to resveratrol and no significant difference was observed
between synthetic and natural promoters in term of
resveratrol-responsiveness as well as therapeutic efficacy
when associated with our gene therapy.
In conclusion, the present study confirmed the
potential of synthetic promoters based on isolated CArG
elements to selectively control therapeutic gene expression
in the tumor and the feasibility of GADD45α to work as a
therapeutic drug. Currently, our gene therapy is associated
with resveratrol that is nontoxic and protective to normal
cells but may have low bioavailability due to rapid
metabolism. In future, this gene therapy vector may work

Figure 4: Resveratrol is not sufficient to activate GADD45α. A. and B. GADD45α protein expression and mRNA level were

measured by western blotting and real-time RT PCR after cells were treated with 100 µM of resveratrol for various hours. C. Cells were
treated with or without resveratrol overnight and performed anti-GADD45α immunofluorescent staining. Images were taken on Axio
Imager M2 at 400X magnification.
www.impactjournals.com/Genes&Cancer
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Figure 5: Both synthetic and natural promoters are able to overexpress GADD45α to induce cell apoptosis when
combined with resveratrol. A. Cells were co-transfected with luciferase constructs containing either the synthetic CArG promoter (pE5,

pE6 and pE9NS) or the natural Egr-1 promoter (pE460) and Renilla luciferase control reporter vector (pRL-TK) followed by resveratrol
or non-treatment. Relative luminescence was plotted as the average of triplicate experiment and represented as mean ± SE. B. Level of
GADD45α protein was detected by western blotting after cells were transfected with either suicide gene therapy vector (pE460.G45α or
pE9NS.G45α) or control vector (pT.Luc) and then treated with or without 100 µM of resveratrol for 24 h. C. MTT assay was performed
for cells pre-transfected with pE460.G45α, pE9NS.G45α or pT.Luc and treated with different doses of resveratrol for 24 h. D. Cells were
exposed to 100 µM of resveratrol for 24 h after transfected with control or suicide gene therapy constructs. Apoptosis was determined by
FACS of Annexin V-FITC and PI stained cells.

www.impactjournals.com/Genes&Cancer
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Quantitative real-time polymerase chain reaction
(qRT-PCR)

synergistically with traditional lung cancer treatment such
as radiation therapy and chemotherapy, and achieve better
therapeutic effects even with low doses of radiotherapy
and chemotherapy and simultaneously reduce the damage
to normal tissues. Moreover, since GADD45α-induced
apoptosis is not p53 dependent, our gene therapy may
benefit patients regardless of p53 status in their tumors.
Further investigation will be conducted with low doses
of radiation and multiple chemotherapeutic agents in cell
lines with various p53 status (Shi et al., Manuscript in
preparation).

Total RNA was isolated from 1 x 106 A549 cells
treated with 100 µM of resveratrol for various hours
using Column-PureTM total tissue RNA isolation kit
(Lamda Biotech, MO) according to manufacturer’s
recommendation. Reserve transcription reactions were
carried by using AccuPower® RT PreMix (Bioneers,
NM) following manufacturer’s protocols. Real-time PCR
was carried out using Applied Biosystems® 7900HT fast
Real-time PCR system (Life technologies, CA). The
cDNA generated from reverse transcription was diluted
1:10 and 5μl was utilized to conduct PCR. PCR reactions
were carried out in microAmp® fast optical 96-well
reaction plates (Life technologies, CA) with Evagreen
qPCR master mix (2X) (LAMDA Biotech, MO), forward
and reverse primers (0.3 μM) (Eurofins) in a final PCR
reaction volume of 20 μl. The primers for Egr-1 and the
endogenous control GAPDH were the same as previously
reported [17]. Amplification parameters were: denaturation
at 95°C 10 min, followed by 40 cycles of 95°C, 15 s; 60°C,
60 s. Samples were analyzed in duplicate. Fold induction
was calculated using the formula 2-ΔΔCt, where ΔCt =
target gene Ct - GAPDH Ct, and ΔΔCt is based on the
mean ΔCt of respective control (non-resveratrol treated).

MATERIALS AND METHODS
Cell culture and media
A549, a human lung adenocarcinoma epithelial
cell line, was obtained from the American Type Culture
Collection (Manassas, VA). A549 was maintained
in Dulbecco’s modified Eagle’s medium (DMEM)
(Invitrogen Life Technologies, CA) supplemented with
fetal bovine serum (10% v/v, Invitrogen/Gibco BRL,
CA), penicillin (100 IU/ml) and streptomycin (100 µg/ml,
Sigma, MO) at 37 ºC with 5% CO2. All the cells were
passaged when confluency was reached, usually every 2-4
days.

Simultaneous fluorescence in situ hybridization
and immunofluorescence

Western blot analysis

Simultaneous fluorescence in situ hybridization
(FISH) and immunofluorescence was performed following
the protocol provided by Biosearch Technologies (CA).
5,000 cells were seeded on 18 mm round coverslip
on day one, and treated with 100 µM of resveratrol as
time indicated on day two. Medium was aspirated and
cells were washed with 1X PBS and then fixed with
formaldehyde (3.7% in 1X RNase free PBS) for 10 min.
After the fixation buffer was removed, cells were washed
with 1X PBS twice and permeabilized with 70% ethanol at
4°C overnight. On day four, the ethanol was removed and
wash buffer (10% formamide in 2X saline-sodium citrate
(SSC) was added to cells for 2-5 min. Then the wash
buffer was aspirated and 100 µl of Egr-1 Stellaris FISH
probe (1 µl from 25 µM stock solution) plus GADD45α or
Elk-1 primary antibody (0.5 µg/ml as final concentration)
in hybridization buffer (10% formamide in 2X SSC plus
100 µg/ml of dextran sulfate) was added on a layer of
parafilm. The coverslip was placed over the hybridization
buffer and incubated in a dark humidified chamber at
37°C overnight. On the following day, the coverslip was
removed from hybridization buffer and incubated in 1
ml of wash buffer including 10 µg/ml of corresponding
fluorescently-labeled secondary antibody again at 37°C
for 30 min in the dark. One drop of mounting medium

After transfection or/and resveratrol treatment,
the cells were washed with PBS and then harvested in
RIPA buffer (Teknova, CA) containing 1X phosphatase
inhibitor cocktail I and 1X protease inhibitor cocktail
II (Boston BioProducts, MA). The lysis was sonicated
with Branson 450 analog sonifier for 10 rounds at 20%
duty cycle, 2-output control. Total protein (20-50 µg)
for each sample was separated by electrophoresis on
a 4-20% gel (Bio-Rad, CA) and transferred to 0.45 µm
pore size nitrocellulose membrane (GE Healthcare BioSciences, PA). Each membrane was blocked with 1X
Tris-Buffered Saline and Tween 20 (TBST) (Santa Cruz
Biotechnology, CA) containing 3% fat-free milk and then
incubated overnight with Egr-1 (588), GADD45α (H165), Elk-1 (H-20) and β-actin (C4) (1:200 dilution in 1X
TBST plus 5% Bovine Serum Albumin (BSA) and 0.02%
NaN3; Santa Cruz Biotechnology, CA), respectively.
The following day, the membrane was incubated with a
secondary donkey anti-rabbit IgG or goat anti-mouse IgG
conjugated to peroxidase (Santa Cruz Biotechnology, CA)
and diluted 1:5,000 in 1X TBST with 3% fat-free milk.
Detection was carried out using the SuperSignal West Pico
chemiluminesce substrate (Thermo Scientific, IL).

www.impactjournals.com/Genes&Cancer
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containing 1.5 µg/ml of 4’, 6-diamidino-2-phenylindole
(DAPI) was used to mount cells on the slide. DAPI was
used as a DNA counterstain. The cells were imaged using
Axio Imager M2 from Carl Zeiss at 400X magnification.
Custom Egr-1 probe were designed from Biosearch
technologies, which contained a mix of multiple 20-mer
oligonucleotides, each labeled with a single CAL Fluor
Red 590. Egr-1 probe sets contained 37 oligos.

The final concentrations of all the inhibitors were
10 µM except SP 600125 (BIOMOL International, PA), of
which the concentration was 20 µM. SB 203580 (Promega,
WI) inhibits p38MAPK/SAP2, whereas SP 600125 is a
potent JNK inhibitor. U-0126 (Santa Cruz Biotechnology,
Inc, TX) is a potent inhibitor of ERK1/2 activity and LY
294002 (Santa Cruz Biotechnology, Inc, TX) blocks PI3K/
AKT pathways. Cells were treated with or without 100
µM of resveratrol for another 6 h after 1 h preincubation,
and the expression of Egr-1 protein and β-actin (loading
control) was examined by western blotting.

GACAGATCTGCTTGGAACCAGGGAGGAG
E460R5’TCAACGGGGCGGG
CGATCGCGGCCTCTATTTGAAGGGTCTGG
pT.G45α vector was linearized with fast digest BgIII
and fast digest AsiSI enzymes at 37°C for 15-20 min and
linearized vector was purified by gel purification Qiagen
kit (Qiagen Sciences, MD). Purified PCR fragment and
linearized pT.G45α were mixed and added to dry pellet
of infusion enzyme followed by incubation at 37°C for 15
min and 50°C for 15 min to construct pE460.G45α.
Synthetic Egr-1 enhancer sequences were prepared
using the following oligonucleotides (ODN):
E9NSODN15’-[Phos]
GATCT(CCATATAAGG)9GCGAT-3’
E9NSODN2- 5’-[Phos]CGC(CCTTATATGG)9A-3’
Each pair of ODNs was incubated with 1X oligo
annealing buffer containing 10 mM Tris-HCl pH 8.0, 100
mM NaCl, and 10 mM EDTA at 95°C for 4 min and cool
at room temperature for 5-10 min to create double ODN
(dODN). Ligation between dODN and linearized pT.G45α
was performed by incubating with T4 ligase and T4 ligase
buffer at 22°C for 1 h and then heated at 70°C for 5 min to
create pE9NS.G45α.

In vitro dual-luciferase assay

In vitro transfection

A549 cells were plated at 1 x 104 cells per well in
96-well plate and transfected with the firefly luciferase
reporter constructs (pE460, pE5, pE6, pE9NS). All groups
were co-transfected with the Renilla luciferase construct
pRL-TK to normalize transfection efficiency. After 48 h,
cells were treated with 100 µM of resveratrol overnight,
and luciferase activity was measured using the DualLuciferase reporter assay system (Promega, WA).

All transfections were performed using
magnetofection principle. Briefly, A549 cells were seeded
in various plates in Opti-MEM® containing 10% FBS and
1% NEAA without antibiotics the day before transfection.
When cell confluency reached 90-95%, transfection were
performed using Lipofectamine 2000 (Invitrogen, CA)
and CombiMag reagent (OZ Biosciences) according
manufacturer’s instruction. In general, 2-3 µl of
LipofectamineTM 2000 and 1 µl of CombiMag were used
for the transfection of per µg of DNA or every 40 pmol of
siRNA. After the complexes were added to each well, the
plate was incubated on a magnetic plate for 20 min.

Inhibitor studies

Construction of suicide gene therapy vector
GADD45α open reading frame (ORF) was PCR
amplified from GADD45α cDNA (Origene, MD) using
specific primers:
F5’GGATCCGCCACCATGACTTTGGAGGAATTCTCG -3’
R5’
-ATTCGCGGCCGCTCACCGTTCAGGGAGATTAAT
-3’
pTarget vector was linearized with fast digest
BamHI and fast digest NotI enzymes at 37°C for 10 min
and linearized vector was purified by gel purification
Qiagen kit (Qiagen Sciences, MD). Fusion cloning was
performed with purified GADD45α cDNA and linearized
pTarget using infusion dry HD cloning kit (Clontech
Laboratories, Inc., CA) to create pT.G45α.
460 bp of Egr-1 promoter upstream of start site was
PCR amplified on pEgr-1-luc using specific primers:
E460F5’ATGGCTC
www.impactjournals.com/Genes&Cancer

Cell viability assay
A549 cells (1 x 104 per well) were seeded in 96-well
plates. After transfection and resveratrol treatment, 20 µl
of MTT (5 mg/ml) was added to each well and incubated
for 4 h. Media was exchanged with 100 µL of DMSO and
the absorbance at 570 nm was recorded.

Apoptosis
Cells (5 x 105 per well) were seeded in 6-well plates
and transfected with vector pE9NS.G45α or pT.Luc
for 24 h followed by 100 µM of resveratrol treatment
for additional 24 h. Cells were harvested and stained
with Annexin V-FITC and propidium iodide (PI) using
228
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Apoptosis Detection Kit (Life Technologies, CA). Flow
cytometry was performed using BD AccuriTM C6 and the
data were analyzed by CFlow Plus (BD Biosciences, NJ).

dissociation from the cytoskeleton and translocation to
mitochondria. Mol Cell Biol. 2005; 25: 4488–4500.
13. Cao XM, Koski RA, Gashler A, McKiernan M, Morris
CF, Gaffney R, Hay RV, Sukhatme VP. Identification and
characterization of the Egr-1 gene product, a DNA-binding
zinc finger protein induced by differentiation and growth
signals. Mol Cell Biol. 1990; 10: 1931-1939.
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